#investment-thesis

Myriad Genetics has something many distressed companies do not:

a real business with established products, recognized clinical franchises, and potentially valuable newer technologies.

That is what makes the investment case interesting.

The problem is that those assets are currently sitting inside a company with shrinking revenue, persistent losses, cash burn, and a business model that has not yet demonstrated a clear path back to sustainable profitability.

In other words, this is not a conventional growth thesis.

It is a recovery thesis.

And recovery theses require a higher burden of proof.

This is a snapshot of that thesis as it stands in September 2026.

It is not a recommendation to buy or sell Myriad Genetics shares.

It is an attempt to define what would have to improve, what could create upside, and what developments would signal that the thesis is breaking rather than recovering.

At a Glance

Company: Myriad Genetics
Ticker: MYGN
Thesis type: Distressed recovery / diagnostics / strategic optionality
Snapshot date: September 2026

Why it may be interesting:
Myriad owns established molecular-diagnostics franchises and newer oncology products with potential long-term value. At a heavily depressed valuation, stabilization of revenue and a credible path toward profitability could create substantial upside.

What the market may be underestimating:
The value of Myriad's stronger Cancer Care Continuum franchise, newer tests such as Precise MRD and Prolaris + AI, intellectual property, and potential strategic value if the company restructures or reallocates capital more effectively.

Ardent Health is not an obvious growth stock.

It operates hospitals, clinics, specialty-care centers, and other healthcare facilities across a collection of mid-sized U.S. markets.

That means the investment case depends less on a single product breakthrough and more on something quieter:

Can Ardent steadily improve the economics of delivering healthcare across its existing network?

The answer is not yet obvious.

In 2026, adjusted admissions have continued growing. Cash generation has been strong. Leverage remains manageable. Management has also expanded its cost-savings program and continued investing in new facilities and specialty-care capacity.

At the same time, raw admissions and surgeries have softened, reimbursement per adjusted admission has come under pressure, and quarterly earnings have been uneven.

This is a snapshot of that thesis as it stands in September 2026.

It is not a recommendation to buy or sell Ardent Health shares.

It is an attempt to define what would need to improve, and what would have to deteriorate, for the investment thesis to become stronger or weaker.

At a Glance

Company: Ardent Health
Ticker: ARDT
Thesis type: Operational improvement / healthcare utilization / prove-it
Snapshot date: September 2026

Why it may be interesting:
Ardent is generating strong operating cash flow, maintaining relatively modest leverage, and growing adjusted admissions even while some underlying patient-volume measures remain soft. If operational improvements translate into more consistent earnings, the current valuation could prove attractive.

Mativ Holdings is not an obvious growth story.

It is a specialty-materials company formed in 2022 through the combination of SWM and Neenah, with businesses spanning filtration, engineered films, adhesives, release liners, healthcare materials, packaging, and other industrial applications.

The interesting part of the investment case is not that sales are suddenly exploding.

They are not.

The more interesting question is whether Mativ is becoming a substantially better business while operating with roughly the same revenue base.

In 2026, margins have improved sharply. Free cash flow has strengthened. Debt has started moving downward. And management appears to be extracting more economic value from a complicated collection of businesses assembled through merger and restructuring.

This is a snapshot of that thesis as it stands in September 2026.

It is not a recommendation to buy or sell Mativ shares.

It is an attempt to define what would have to keep improving, and what would have to go wrong, for the turnaround thesis to hold together.

At a Glance

Company: Mativ Holdings
Ticker: MATV
Thesis type: Turnaround / margin expansion / deleveraging
Snapshot date: September 2026

Why it may be interesting:
Mativ has shown two consecutive quarters of sharply improving adjusted EBITDA margins despite little overall revenue growth. If stronger operating efficiency continues producing free cash flow and debt reduction, the equity could benefit disproportionately.

Cenovus Energy is not an obscure speculative oil company.

It is a large integrated Canadian energy producer with upstream oil and gas operations, refining assets, and, after its acquisition of MEG Energy, an even larger footprint in the Canadian oil sands.

That makes the investment question more interesting than simply asking whether oil prices will go up.

The more useful question is whether Cenovus is entering a period in which stronger production, lower costs, acquisition synergies, and falling debt can steadily translate into greater value for shareholders.

This is a snapshot of that thesis as it stands in September 2026.

It is not a recommendation to buy or sell Cenovus shares.

It is an attempt to define what would have to go right, and what would have to go wrong, for the current investment thesis to hold up.

At a Glance

Company: Cenovus Energy
Ticker: CVE
Thesis type: Deleveraging / operational improvement
Snapshot date: September 2026

Why it may be interesting:
Cenovus is combining strong oil-sands production, lower operating costs, MEG integration synergies, and rapid debt reduction. If those trends persist, more future cash flow could shift from deleveraging toward shareholder returns.

What the market may be underestimating:
The combined impact of higher production, lower unit costs, acquisition synergies, and a cleaner balance sheet.

What would strengthen the thesis:

• Net debt continues falling